Voyager Therapeutics NASDAQ: VYGR expects a readout from its tau antibody study in the current quarter and plans to begin dosing patients in its Alzheimer’s gene therapy program in the coming months, CEO Al Sandrock said during a fireside chat.
The two programs are part of what Sandrock described as a “catalyst-rich period” for the company, which is also working with Neurocrine on a gene therapy using one of Voyager’s blood-brain barrier-penetrating capsids for Friedreich’s ataxia.
The studies will provide opportunities to assess whether the capsids can be administered safely and deliver genes that are expressed in patients, Sandrock said. He added that early safety issues related to capsids tend to emerge quickly, while evidence of gene expression in the brain could take about a year after dosing begins.
Gene therapy targets tau reduction
Voyager has received Food and Drug Administration clearance to begin a study of its tau knockdown gene therapy, VY1706. The treatment is designed to use a capsid to deliver genetic material that produces small interfering RNA, or siRNA, inside cells to reduce tau.
Sandrock said the company expects an initial assessment of acute safety in the first quarter. About a year after dosing starts, Voyager plans to measure tau in cerebrospinal fluid. Tau PET imaging would follow, although the company has not provided a timeline for that assessment.
On capsid-related safety, Sandrock said Voyager plans to use a maximum dose of no more than 5E13 vector genomes per kilogram. He also said its capsid targets the liver 30-fold less than AAV9 and that patients will receive immunosuppressive treatment around administration. The company’s toxicology studies were promising, he said, and Voyager incorporated FDA feedback into its testing.
Sandrock said animal studies showed tau could be reduced by as much as 70% without adverse effects. He also cited human genetic variants associated with tau loss of function as a source of reassurance, while acknowledging the importance of monitoring safety in patients.
Reading across from other tau programs
Sandrock said results from Biogen’s BIIB080 and other tau-targeting programs support tau as a therapeutic target, despite BIIB080’s failure on its primary endpoint, a dose-response measure based on the CDR Sum of Boxes scale.
He attributed the lack of a stronger dose response in part to transient acute confusional states that increased with dose, an interpretation he said may relate to off-target effects of intrathecally administered antisense oligonucleotides. That explanation was his assessment, not an established finding.
Voyager’s approach differs because its siRNA is produced inside cells, rather than administered intrathecally, Sandrock said. He also cited high-level data from Arrowhead’s systemically delivered siRNA program, in which an acute confusional state or encephalopathy was not reported.
Antibody data expected in fourth quarter
Sandrock called Voyager’s tau antibody a “dark horse,” noting skepticism about antibody approaches to tau. He said the antibody is designed to target pathological forms of the protein and was selected using a mouse model intended to assess tau accumulation and spread.
The multiple-ascending-dose study is powered to measure an effect on tau PET imaging, with results expected in the fourth quarter, he said. Sandrock said he does not expect a reduction in the PET signal, but hopes to see slower accumulation and spread. He cited bepranemab as a benchmark, saying Voyager would want to exceed its roughly 50% effect.
If the data are positive, Voyager could potentially advance the antibody into a Phase 2 study, Sandrock said, although he added that the company would need a partner at some point for an Alzheimer’s program. He said he plans to step down as CEO in the coming months and that his successor, Robin Swartz, would make the decision on next steps.
More shuttle data planned
Sandrock also discussed Voyager’s ALPL shuttle, which is designed to transport therapies across the blood-brain barrier. He said the company plans to present mouse and nonhuman primate data at an antibody engineering meeting in San Diego the following month.
He said ALPL has a more restricted distribution in the body than transferrin receptors, which are used in other shuttle approaches. Voyager has also examined bone-related safety measures because severe loss-of-function mutations in ALPL can cause bone mineralization problems, he said.
About Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company's TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.